Skip to content
ATLAS PREP HQ
Healing

GLOW

Blend of GHK-Cu + BPC-157 + TB-500

Multi-peptide blend combining GHK-Cu, BPC-157, and TB-500 for broad tissue-repair research.

Preclinical Evidence

Route

Subcutaneous research blend.

Common format

GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg

Research focus

skin/tissue repair

Evidence level

Preclinical Evidence

Typical cycle

4 weeks

Healing research motifHealing

GLOW in 30 seconds

Atlas Fast Read

What it is

Blend of GHK-Cu + BPC-157 + TB-500

Why people care

Multi-peptide blend combining GHK-Cu, BPC-157, and TB-500 for broad tissue-repair research.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

The blend has no controlled human efficacy data, and its formulation itself is disputed. Key gaps include pH compatibility, copper displacement/oxidation, peptide aggregation, real post-mix potency, sterility, pharmacokinetics and long-term safety.

Bottom line

GLOW is scientifically interesting for skin/tissue repair, collagen, but the current case is driven mainly by cell and animal data.

Overview

What is GLOW?

GLOW is a multi-compound research blend rather than a single peptide. It combines several repair- and inflammation-oriented peptides in one formulation, so any claim about the blend must be separated from evidence on its individual ingredients.

GLOW is a modern compounded/research blend rather than a historically developed single molecule. It packages GHK-Cu, BPC-157, and TB-500 into one vial for convenience.

Mechanism

How it works

The blend combines copper-dependent matrix remodeling (GHK-Cu), BPC-157's proposed cytoprotective/angiogenic signaling, and thymosin-beta-4-related cell migration and actin remodeling. The mixture itself has not been clinically validated.

Research areas

skin/tissue repaircollagenwound healingrecovery

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No human clinical trials validate GLOW as a fixed GHK-Cu + BPC-157 + TB-500 blend. Any human rationale is indirect and based on separate ingredients, with the strongest human data belonging to topical GHK-Cu rather than the injectable mixture.

Preclinical evidence

There is no meaningful preclinical evidence on the exact fixed blend. The rationale is assembled from separate GHK-Cu, BPC-157, and thymosin-beta-4/TB-500 literature.

Knowledge gaps

The blend has no controlled human efficacy data, and its formulation itself is disputed. Key gaps include pH compatibility, copper displacement/oxidation, peptide aggregation, real post-mix potency, sterility, pharmacokinetics and long-term safety.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources blend reference: 2.33 mg total/day, approximately 1.7 mg GHK-Cu + 0.33 mg BPC-157 + 0.33 mg TB-500.

Frequency

Once daily.

Timing

No validated timing advantage.

Route

Subcutaneous research blend.

Cycle length

4 weeks

Reconstitution

Community sources list 3 mL bacteriostatic water per 70 mg blend. However, community sources raises a material formulation concern: GHK-Cu, BPC-157 and TB-500 have different stability/pH requirements, so a fixed mixed vial may lose potency or degrade. Atlas should display this conflict rather than treating the blend as chemically validated.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C and use within 4 weeks.

Monitoring

No clinical monitoring standard for the blend. Track wound/injury/skin outcomes, injection reactions and general CBC/CMP. Compatibility and degradation of multi-peptide blends are important uncertainties.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.

Contraindications

No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.

Interactions

Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.

Stacks

Common stacks

GLOW blend

This entry is already a GHK-Cu + BPC-157 + TB-500 blend.

No controlled human evidence on the fixed blend; chemical compatibility/stability is a separate concern.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

GLOW is scientifically interesting for skin/tissue repair, collagen, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide